Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 21 studies | 51% ± 14% | |
brain | 21 studies | 40% ± 20% | |
peripheral blood | 20 studies | 56% ± 15% | |
intestine | 12 studies | 42% ± 18% | |
eye | 11 studies | 42% ± 18% | |
kidney | 10 studies | 45% ± 15% | |
liver | 7 studies | 50% ± 20% | |
lymph node | 6 studies | 51% ± 17% | |
heart | 6 studies | 29% ± 7% | |
pancreas | 5 studies | 64% ± 24% | |
bone marrow | 5 studies | 44% ± 16% | |
placenta | 5 studies | 52% ± 26% | |
uterus | 5 studies | 58% ± 15% | |
adipose | 5 studies | 34% ± 8% | |
prostate | 5 studies | 56% ± 24% | |
breast | 5 studies | 52% ± 18% | |
esophagus | 4 studies | 47% ± 24% | |
skin | 4 studies | 42% ± 21% | |
adrenal gland | 3 studies | 46% ± 14% | |
thymus | 3 studies | 63% ± 24% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 16333.07 | 459 / 459 | 100% | 96.84 | 1118 / 1118 |
esophagus | 100% | 13646.35 | 1445 / 1445 | 100% | 63.42 | 183 / 183 |
intestine | 100% | 14454.24 | 966 / 966 | 100% | 73.35 | 527 / 527 |
kidney | 100% | 14222.76 | 89 / 89 | 100% | 80.75 | 901 / 901 |
liver | 100% | 11070.43 | 226 / 226 | 100% | 47.98 | 406 / 406 |
lung | 100% | 19313.81 | 578 / 578 | 100% | 79.46 | 1155 / 1155 |
ovary | 100% | 15243.74 | 180 / 180 | 100% | 63.23 | 430 / 430 |
pancreas | 100% | 8550.49 | 328 / 328 | 100% | 77.63 | 178 / 178 |
prostate | 100% | 13304.61 | 245 / 245 | 100% | 78.66 | 502 / 502 |
stomach | 100% | 11389.64 | 359 / 359 | 100% | 66.67 | 286 / 286 |
uterus | 100% | 14238.69 | 170 / 170 | 100% | 83.59 | 459 / 459 |
thymus | 100% | 14498.43 | 653 / 653 | 100% | 88.62 | 604 / 605 |
bladder | 100% | 15283.76 | 21 / 21 | 100% | 74.73 | 503 / 504 |
adrenal gland | 100% | 18072.76 | 258 / 258 | 100% | 73.21 | 229 / 230 |
brain | 100% | 9359.99 | 2630 / 2642 | 100% | 76.72 | 705 / 705 |
skin | 100% | 16005.68 | 1809 / 1809 | 99% | 75.40 | 469 / 472 |
adipose | 100% | 17951.87 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 15329.32 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 94.65 | 29 / 29 |
muscle | 100% | 17552.04 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 15586.63 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 90.81 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 30.17 | 1 / 1 |
peripheral blood | 100% | 17759.43 | 925 / 929 | 0% | 0 | 0 / 0 |
heart | 98% | 11077.75 | 845 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 55.66 | 78 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0006281 | Biological process | DNA repair |
GO_0070979 | Biological process | protein K11-linked ubiquitination |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0051865 | Biological process | protein autoubiquitination |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0030514 | Biological process | negative regulation of BMP signaling pathway |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0036211 | Biological process | protein modification process |
GO_0006915 | Biological process | apoptotic process |
GO_1903955 | Biological process | positive regulation of protein targeting to mitochondrion |
GO_0006513 | Biological process | protein monoubiquitination |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0085020 | Biological process | protein K6-linked ubiquitination |
GO_0000151 | Cellular component | ubiquitin ligase complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0010008 | Cellular component | endosome membrane |
GO_0005634 | Cellular component | nucleus |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0005524 | Molecular function | ATP binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0061631 | Molecular function | ubiquitin conjugating enzyme activity |
GO_0005515 | Molecular function | protein binding |
Gene name | UBE2D3 |
Protein name | Ubiquitin-conjugating enzyme E2 D3 (EC 2.3.2.23) (EC 2.3.2.24) ((E3-independent) E2 ubiquitin-conjugating enzyme D3) (E2 ubiquitin-conjugating enzyme D3) (Ubiquitin carrier protein D3) (Ubiquitin-protein ligase D3) Ubiquitin-conjugating enzyme E2 D3 (EC 2.3.2.23) ((E3-independent) E2 ubiquitin-conjugating enzyme D3) (EC 2.3.2.24) (E2 ubiquitin-conjugating enzyme D3) (Ubiquitin carrier protein D3) (Ubiquitin-conjugating enzyme E2(17)KB 3) (Ubiquitin-conjugating enzyme E2-17 kDa 3) (Ubiquitin-protein ligase D3) Ubiquitin conjugating enzyme E2 D3 E2 ubiquitin-conjugating enzyme (EC 2.3.2.23) |
Synonyms | UBCH5C UBC5C |
Description | FUNCTION: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins . In vitro catalyzes 'Lys-11'-, as well as 'Lys-48'-linked polyubiquitination . Cooperates with the E2 CDC34 and the SCF(FBXW11) E3 ligase complex for the polyubiquitination of NFKBIA leading to its subsequent proteasomal degradation . Acts as an initiator E2, priming the phosphorylated NFKBIA target at positions 'Lys-21' and/or 'Lys-22' with a monoubiquitin . Ubiquitin chain elongation is then performed by CDC34, building ubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin . Acts also as an initiator E2, in conjunction with RNF8, for the priming of PCNA . Monoubiquitination of PCNA, and its subsequent polyubiquitination, are essential events in the operation of the DNA damage tolerance (DDT) pathway that is activated after DNA damage caused by UV or chemical agents during S-phase . Associates with the BRCA1/BARD1 E3 ligase complex to perform ubiquitination at DNA damage sites following ionizing radiation leading to DNA repair . Targets DAPK3 for ubiquitination which influences promyelocytic leukemia protein nuclear body (PML-NB) formation in the nucleus . In conjunction with the MDM2 and TOPORS E3 ligases, functions ubiquitination of p53/TP53 . In conjunction with the CBL E3 ligase, targets EGFR for polyubiquitination at the plasma membrane as well as during its internalization and transport on endosomes . In conjunction with the STUB1 E3 quality control E3 ligase, ubiquitinates unfolded proteins to catalyze their immediate destruction . Together with RNF135, catalyzes the viral RNA-dependent 'Lys-63'-linked polyubiquitination of RIGI to activate the downstream signaling pathway that leads to interferon beta production . Together with ZNF598, catalyzes ubiquitination of 40S ribosomal proteins in response to ribosome collisions . In cooperation with the GATOR2 complex, catalyzes 'Lys-6'-linked ubiquitination of NPRL2 . . |
Accessions | D6RIZ3 ENST00000338145.7 [P61077-1] ENST00000453744.7 [P61077-1] ENST00000350435.11 ENST00000394804.6 [P61077-1] ENST00000502563.5 ENST00000321805.11 [P61077-1] ENST00000503418.5 D6R9F6 ENST00000394803.9 [P61077-1] ENST00000514755.5 ENST00000505307.5 ENST00000508249.1 D6R933 ENST00000343106.9 [P61077-2] ENST00000504211.5 ENST00000508476.5 A0A087WY85 ENST00000394801.8 [P61077-1] ENST00000507845.5 ENST00000505207.5 ENST00000502690.5 D6RAW0 ENST00000357194.10 [P61077-3] D6RAH7 D6RJB3 D6RGD0 D6R980 ENST00000508974.5 ENST00000349311.12 [P61077-1] ENST00000508238.5 D6RA11 ENST00000508635.5 ENST00000510129.5 H9KV45 ENST00000502404.5 P61077 ENST00000618836.4 |